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We report the design, synthesis, characterization and in vitro testing of a novel nanodrug based on a
covalent linking model that allows intracellular controlled release of the pharmaceutical payload. A new
synthetic strategy is implemented by direct coupling of as-synthesized (pyridin-2-yldisulfanyl)alkyl
carbonate derivatives of camptothecin (CPT) with thiol groups of silica hybrid nanoparticles containing
a non-porous core and a mesoporous shell. Upon reaction with thiols in physiological conditions, disulfide
bridge cleavage occurs, releasing the naked drug after an intramolecular cyclization mechanism.
Additional incorporation of a fluorophore into particles core facilitates imaging at the subcellular level
for the monitoring of uptake and delivery. Confocal microscopy experiments in HeLa cervix cancer cells
confirms that nanoparticles enter the cells by endocytosis but are able to escape from endo-lysosomes and
enter the cytosolic compartment to release their cargo. The incorporation to cells of L-buthionine-
sulfoximine, a glutathione inhibitor allows concluding that the intracellular releasing mechanism is mainly
driven by the reducing activity of this tripeptide. This camptothecin nanoplatform shows the same
cytotoxic activity than the free drug and is clearly superior to those release systems depending on
enzymatic hydrolysis (as determined by calculation of the IC50 ratios).
Introduction
The administration of cytotoxic drugs, like antitumorals,
constitutes a major challenge for the clinical practice. Very
frequently, their poor pharmaceutical profile and serious
undesired effects precludes their practical use in humans.1–3
In this sense, the delivery strategy in chemotherapy has been
mostly focused on stimuli-responsive systems that promote
controlled release of their payload inside the target cells.4–7
Here, redox-sensitive, disulfide-based mechanisms have
shown significant efficiency for selective intracellular release,
based mainly in glutathione-driven cleavage.8,9 Otherwise,
mesoporous silica nanoparticles (MSN) have been proposed
for the delivery and controlled release of small therapeutic
molecules and for theranostic systems, due to their large
surface area, tunable pore size, multifunctionality and good
biocompatibility,10–13 and they look like good candidates as
vehicles for the delivery of covalently linked anticancer
compounds such as camptothecin and paclitaxel.14,15
Unfortunately, the direct coupling of these molecules to an
inorganic nanoparticle is circumvented by the reduced
therapeutic activity of the structure-modified derivatives.16 It
would be desirable to develop covalent linking models that
allow for the controllable release of the free drug after cell
entry.17 Secondly, it is necessary to establish precisely when,
where and how the pharmaceutical payload is released into the
cells. To address these targets, we have developed a novel
camptothecin nanoplatform based in a mercapto-functiona-
lized silica hybrid containing a non-porous core and a
mesoporous shell. A new synthetic strategy has been imple-
mented by reacting novel (pyridin-2-yldisulfanyl)alkyl carbo-
nate derivatives of camptothecin (CPT, a topoisomerase I
inhibitor)18,19 with thiol groups of the inorganic support. This
allowed us to attach the drug over the pores of the external
coating by a cleavable disulfide linker, sensitive to thiols such
as glutathione (GSH) or dithiothreitol (DTT), which are able to
aInstituto de Tecnologı́a Quı́mica (UPV-CSIC), Av. Los Naranjos s/n, 46022 Valencia,
Spain. E-mail: pbotella@itq.upv.es; Fax: (+34) 96-3879444; Tel: (+34) 96-3877819
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release the naked molecule after an intramolecular cyclization
mechanism. In vitro biological evaluation of this delivery
platform has been done on a HeLa cervix cancer cell line.
Furthermore, in order to state the mechanisms for cell uptake,
internal trafficking and controlled release, we have incorpo-
rated a fluorophore (Rhodamine-B, RhB) into the core of the
inorganic vehicle, facilitating imaging at the subcellular level.
Experimental section
All reagents and solvents were purchased from Sigma-Aldrich
except HPLC solvents (HPLC grade from Scharlab or LC/MS
grade Optima from Fisher).
HeLa cells were originally obtained from the American Type
Culture Collection (Rockville, MD) maintained in RPMI media
supplemented with 10% fetal bovine serum (FBS, from Lonza,
Verviers, Belgium) at 37 uC under a humidified atmosphere of
95% air and 5–10% CO2.
Synthesis of camptothecin prodrugs
(Pyridin-2-yldisulfanyl)alkyl carbonate derivatives of CPT were
synthesized according to Scheme 1. The purity of all obtained
molecules was determined by RP-HPLC and the chemical
structure was confirmed by 1H NMR, 13C NMR and Q-TOF MS
analysis (see supplementary information3).
Compounds 2a–c were synthesized following procedures
reported earlier.20 Briefly, to a solution of 2-aldrithiol (4.71 g,
21.4 mmol) in methanol purged with nitrogen (20 mL) was
added dropwise 2-mercaptoethanol (0.50 mL, 7.1 mmol),
3-mercaptopropanol (0.61 mL, 7.1 mmol) or 4-mercapto-1-
butanol (0.717 mL, 7.1 mmol) dropwise. The reaction was
allowed to stir for 2 h. The solvent was removed under reduced
pressure. The yellow oil obtained was purified by flash
chromatography using a mixture of DCM–methanol (95 : 5 v/
v) to afford the corresponding (pyridin-2-yldisulfanyl) alcohol:
2a (985 mg, 80%, assay 85%), 2b (931 mg, 64%, assay 99%) or
2c (1.267 g, 83%, assay 93.5%).
For the preparation of prodrugs 4a–c, different synthetic
routes from literature have been appreciably modified.21–25 To
a solution of DMAP (225 mg, 1.8 mmol) and CPT (150 mg, 0.43
mmol) in anhydrous CH2Cl2 (30 mL), triphosgene (66 mg, 0.24
mmol) was added at room temperature (4a) or at 0 uC (4b–c).
After 15 min, 2a–c (0.7 mmol) was added. The solution was
allowed to react at room temperature (4a) or 0 uC (4b–c) for 16
h (4a–b) or 5 h (4c) under an argon atmosphere. The reaction
was quenched by washing with fresh water. The organic layer
was washed with brine and dried using anhydrous MgSO4. The
solvent was removed under reduced pressure. The yellowish
Scheme 1 Synthetic route to CPT prodrugs and release mechanism of the drug.












































oil was dissolved in the minimum amount of hot methanol
and stored at 4 uC for 48 h. The off-white solid was filtered and
washed with methanol and then dried under vacuum to yield
the corresponding (pyridin-2-yldisulfanyl)alkyl carbonate
camptothecin: 4a (165 mg, 67%, assay 95%), 4b (109 mg,
44%, assay 90%) or 4c (25 mg, 10%, assay 70%).
Synthesis of the CPT nanoplatform
To a mixture of Triton-X100 (53 mL), hexanol (54 mL) and
cyclohexane (225 mL) was added 2 mL of a TMR-APTES
solution (7 mg mL21),26 water (15 mL) and NH4OH (3 mL, 30%
v/v). The mixture was allowed to stir for 30 min. Then, TEOS (3
mL) was added and the reaction was allowed to stir for 24 h.
The fluorescent cores were isolated by centrifugation (30 000
g, 15 min) and washed twice with ethanol and deionised water.
These cores were suspended in ultra-pure water (3 mL) and
mixed with a solution of CTAB (100 mL, 8 mM) and NaOH (1
mL, 100 mm). Then, a TEOS solution in ethanol (0.3 mL, 20%
v/v) was added three times every 30 min. The mixture was
allowed to stir for 2 h at 60 uC and afterwards a solid was
separated by centrifugation (12 500 g, 15 min) and washed
with ethanol. Remaining in pores, CTAB was extracted for 20 h
at 80 uC with 20 mL of a mixture of ethanol–n-heptane (48 : 52)
containing HCl 0.15 M. The solid was again centrifuged
(12 500 g, 15 min), washed with ethanol and freeze-dried. 170
mg of the core-shell nanoparticles (RhB-SiO2@MSN) were
dried under vacuum at 75 uC for 6 h. Then, anhydrous toluene
(0.5 mL) and MPTMS (0.32 mL) was added, and the mixture
was stirred at 120 uC for 16 h. Hybrid nanoparticles were
filtered and washed with toluene and methanol. 100 mg RhB-
SiO2@MSN-SH particles were suspended in DTT solution (10
mL, 100 mM) and stirred for 30 min. Then, the suspension was
centrifuged (12 500 g, 15 min) and the solid obtained was
washed with methanol. Afterwards, 4a solution (3.3 mL in
DMSO, 10 mg mL21) and methanol (16 mL) was added, and
the mixture was stirred for 16 h. Then, the suspension was
centrifuged (12 500 g, 15 min) and the obtained solid (RhB-
SiO2@MSN-SS-CPT) was washed with methanol repeatedly
until no rest of 4a or CPT was detected by UV-Vis (A368), and
was freeze-dried.
Materials characterization
Powder X-ray diffraction patterns (XRD) were collected using a
Philips X’Pert diffractometer equipped with a graphite mono-
chromator, operating at 40 kV and 45 mA and employing
nickel-filtered Cu-Ka radiation (l = 0.1542 nm). Nitrogen gas
adsorption isotherms were measured in a Micromeritics
Flowsorb apparatus. Surface area calculations were carried
out using the BET method, whereas pore size distribution was
calculated according to the Kruk-Jaroniec-Sayari estimation.27
The nanoparticles’ morphology was studied by transmission
electron microscopy (TEM) in a Philips CM-10 microscope
operating at 100 kV. Samples were dispersed in methylchloride
and transferred to carbon coated copper grids. Particle size
and Z-potential measurements were conducted by diffuse light
scattering (DLS), using a Zetasizer Nano ZS (Malvern
Instruments Ltd., Worcestershire, United Kingdom). Dried
materials were re-suspended in deionized water at a concen-
tration of 5 mg mL21 and DLS measurements were performed
at 25 uC and 173u scattering angle. The mean hydrodynamic
diameter was determined by cumulant analysis. Magic angle
spinning-nuclear magnetic resonance (MAS-NMR) spectra
were recorded at room temperature under magic angle
spinning (MAS) on a Bruker AV400 spectrometer, with a 7
mm Bruker BL-7 probe at sample spinning rate of 5 kHz. The
single pulse 29Si spectra were acquired using pulses of 3.5 ms
corresponding to a flip angle of 3p/4 rad and a recycle delay of
240 s, and referred to tetramethylsilane (TMS). The 1H to 13C
cross-polarization spectra were acquired by using a 90 pulse
for 1H of 5 ms, a contact time of 5 ms and a recycle of 3 s, and
referred to adamantine. Diffuse-reflectance (DR) UV-vis spectra
were collected on a Cary 5 equipped with a ‘Praying Mantis’
attachment from Harric.
Redox-sensitive release of CPT
To evaluate the release of CPT from conjugates 4a–c, 950 mL
PBS and 50 mL of a prodrug solution (5 mg mL21) were mixed
in a 1.5 mL eppendorf tube. Then, 3.1 mg GSH was added to
the solution to reach a 10 mM reducing agent concentration
and the tube was placed at a Thermomixer1 equipment at 37
uC and 1350 rpm. After 24 h the sample was freeze-dried and
further dissolved with 950 mL methanol and 50 mL HCl 1 M
solution. This sample was analyzed by RP-HPLC and ESI-MS.
The release of CPT from nanodrug RhB-SiO2@MSN-SS-CPT
was monitored by placing 5 mg material in a vial with 1 mL
PBS solution. The tube was vigorously shaken using a vortex
for 30 s. Then the suspension was placed in a Thermomixer1
at 37 uC and 1350 rpm. After 2 h, 3.1 mg GSH was added to the
solution to reach 10 mM concentration of reducing agent. At
the corresponding time the sample was centrifuged (12 500 g,
15 min) and the supernatant was freeze-dried and further
dissolved with 950 mL methanol and 50 mL HCl 1 M solution.
This sample was analyzed by RP-HPLC and ESI-MS. Triplicate
samples were run for every experiment.
Cytotoxicity study
HeLa cells (4000 cells per well, 96-well plates) were seeded and
stabilized for 48 h in RPMI supplemented with 10% fetal
bovine serum (FBS) and 1% antibiotic (Streptomycin/
Penicillin) at 37 uC in 95% air and 5% CO2 environment.
After incubation, growth medium was exchanged before
further additions. Then, cells with fresh medium were treated
with CPT loaded nanocarrier, 4a compound (in DMSO) or CPT
(in DMSO), with final doses ranging from 0.025 to 2.5 mg mL21
(in CPT equivalents). After 72 h, MTT solution in PBS was
added at a final concentration of 0.2 mg mL21 to the wells and
4 h later formazan crystals were dissolved in DMSO and
spectrophotometrically measured at 550 nm (Perkin-Elmer
VictorX5 Microplate Reader). IC50 calculation survival data
were evaluated by variable slope curve-fitting using Prism 5.0
software (GraphPad, San Diego, CA). Three independent
experiments were performed for every sample, and each
experiment was carried out with five points per concentration.
Cell internalization and intracellular CPT release
10 mg mL21 in CPT equivalents of RhB-SiO2@MSN-SS-CPT was
incubated for 24 h with HeLa cells. After washing excess
nanoparticles with sterile PBS, cells were incubated for 15 min












































with 10 mM Lysotracker Green (Invitrogen), fixed with 4%
paraformaldehyde and mounted with Prolong1 (Invitrogen)
mounting media. Internalization of labeled nanoparticles was
analyzed by confocal microscopy (Olympus FV1000 Confocal
and Spectral Microscope) using excitation peaks at 488/561 nm
and emission at 522/585 nm for Lysotracker and RhB,
respectively. Images were acquired at 606 magnification at
every mm, with an optical resolution of about 800 nm.
Intracellular CPT release was estimated by seeding HeLa
cells in p10 plates (3000 cells per plate) containing RPMI
supplemented with 10% FBS. After 24 h, growth medium was
exchanged and cells were incubated with 20 nM in CPT
equivalents of RhB-SiO2@MSN-SS-CPT. After 24, 48 and 72 h,
cells were washed with PBS, trypsinized and lysed by
sonication. Intracellular contents collected after centrifugation
(500 mL) were treated with 5% TCA aqueous solution at 4 uC
(500 mL). The protein precipitate was removed by centrifuga-
tion (9000 g, 10 min, 4 uC), and the supernatant was freeze-
dried and further dissolved with 950 mL methanol and 50 mL
HCl 1 M solution. Then, the released CPT was determined by
RP-HPLC and ESI-MS. Triplicate samples were run for every
experiment.
Inhibition of intracellular CPT release
HeLa cells (4000 cells per well, 96-well plates) were seeded and
stabilized for 24 h in RPMI supplemented with 10% fetal
bovine serum (FBS) at 37 uC in 95% air and 5% CO2
environment. Next, L-buthionine sulfoximine (BSO, 0–1 mM)
or chloroquine (CLQ, 0.15 mM) was added, and cells were
incubated for a further 24 h. After incubation, growth medium
was exchanged and cells with fresh medium were treated with
RhB-SiO2@MSN-SS-CPT or CPT (in DMSO), with final doses
ranging from 0.025 to 2.5 mg mL21 (in CPT equivalents). After
72 h, IC50 calculation survival data were evaluated as described
above. Three independent experiments were performed for
every sample, and each experiment was carried out with five
points per concentration.
Results and discussion
Synthesis of prodrugs and CPT nanoplatform
A major obstacle in implementing our aim was the synthetic
difficulty of coupling a disulfide-derivative of CPT to an
inorganic support. While prodrugs of CPT with cleavable
disulfide linkers that release the unaltered drug have been
developed, no information was available on its direct attach-
ment to a nanoparticulated transporter.21–25 We therefore
performed a singular synthetic strategy based on the direct
incorporation of CPT prodrugs on the nanocarrier. For this
purpose, we first synthesized novel (pyridin-2-yldisulfanyl)alkyl
carbonate derivatives of CPT, according to Scheme 1 (com-
pounds 4a–c). These elaborated systems were thus expected to
release CPT upon disulfide cleavage by GSH.
All compounds were characterized by 1H NMR, 13C NMR and
Q-TOF analysis (see Supplementary3 Fig. S1–S4).
The sensitivity to reducing agents of the conjugates 4a–c was
assayed by measuring (RP-HPLC and ESI-MS) their decom-
position when incubated 24 h at 37 uC in phosphate buffered
saline (PBS, 1x, pH 7.4) with 10 mM GSH. Disulfide cleavage
took place in 1 h in all cases (Scheme 1). However, the desired
following intramolecular cyclization and cleavage of the
neighboring carbonate bond of 5a–c to yield free CPT, CO2
and the corresponding thiolactone only happened quantita-
tively for the 5a compound. Conversely, carbonate 5b released
only 68% CPT and 5c showed less than 50% of the therapeutic
molecule. This pattern of stability of the carbonate derivative
correlates to the increasing distance between the carbonyl
group and the proximal sulfur atom, and agrees strongly with
the behavior observed for similar disulfide conjugates of
luciferin.20
Although all three conjugates were sufficiently stable for
coupling to mercapto-functionalized silica nanoparticles, only
the most sensitive carbonate to reducing agents was selected
to react with surface thiol groups. First, nonporous silica cores
doped with RhB were synthesized by co-condensation of
tetramethylrhodamine B isothiocyanate (TRITC) modified with
3-aminopropyltriethoxysilane (APTES) to form TMR-APTMS26
with tetraethyl orthosilicate (TEOS) and then, a mesoporous
silica wall was grown by silicate polymerization in the presence
of the cationic cetyltrimethylammonium bromide (CTAB) and
further removal of the organic template with ethanol.28 The
obtained core–shell nanoparticles were reacted with (3-
mercaptopropyl)trimethoxysilane (MPTMS) to produce RhB-
SiO2@MSN-SH. Subsequently, 4a was covalently coupled with
the inorganic support by disulfide bond, as shown in Fig. 1.
Particles with a diameter of around 50–60 nm, a non-porous
core and a wormhole-like mesoporous shell (BET area = 139.4
m2 g21, pore diameter = 34 Å) were synthesized (Fig. 2a). It is
noticeable that, although rarely, some particle dimers and
trimers were also found in TEM images, due to simultaneous
growth of the mesoporous silica wall of several nanoparticles
together (see supplementary information3 Fig. S5). Zeta
potential measurements confirmed stable colloids in aqueous
medium with negative charge on surface (f = 217.0 ¡ 6.6 mV).
Nevertheless, some polydispersion was observed by DLS (PI =
0.152, average hydrodynamic diameter = 91 ¡ 35 nm, volume
output), probably corresponding to the small quantity of
nanoparticles dimmers and trimmers detected by electronic
microscopy.29 Diffuse reflectance UV-vis spectroscopy of RhB-
SiO2@MSN-SS-CPT showed broad absorption bands at 368 nm
(CPT) and 560 nm (RhB, Fig. 2b). The loading of these
molecules was 4.7% of the dye (as determined by elemental
analysis) and 3.5% of the drug (as measured by RP-HPLC after
release, see below). Material structural and physico-chemical
characterization was completed by powder XRD and MAS-NMR
(see supplementary information 3 Fig. S6–S10 and Table S1).
In order to investigate the drug release behavior of RhB-
SiO2@MSN-SS-CPT, GSH 10 mM was used as an external
stimulus to trigger the redox-responsive mechanism, as this
compound is the major small molecule reducing agent in the
cytoplasm. Former non-specific release in PBS of 0–2% was
observed within 2 h at 37 uC by RP-HPLC and ESI-MS,
indicating a good stability of the linker system (Fig. 3). Then,
addition of GSH for disulfide bond cleavage led to a burst
initial release of CPT (about 40% in 3 h) followed by a slower
release that was completed after 72 h (.95% after 48 h). We












































are aware that some intermediate compounds as 5a and mixed
disulfides of GSH with the prodrug could be formed during
this process. However, under our analytical conditions none of
these intermediates was detected. Therefore, we assume that
such a slow release of CPT is due to the lower GSH
concentration and its moderate reduction potential.30 In fact,
the system was much more sensitive to a stronger thiol-
reducing molecule like DTT (see supplementary information3
Fig. S11).
In any case, this novel nanoplatform showed high resistance
to hydrolysis in cell uptake experimental conditions, as we
detected only about 8% of CPT released after 24 h incubation
in conditioned cell culture medium (RPMI supplemented with
10% FBS after 24 h contact with HeLa cells, see Fig. S12 in
Supplementary Information3). Furthermore, we know that
following endocytosis the particles are likely to be exposed to
low pH at the endo-lysosomal compartments that could trigger
the premature release of the drug molecule (before reaching
the cytosol). In order to check this, we incubated the
nanoparticle in an acid buffer solution (pH 5.5) for 24 h.
The results (Fig. S12, ESI3) show that the carbonate-disulfide
linking system is consistently resistant to proton concentra-
tion in endocytic vacuoles.
Fig. 1 Preparation of the novel therapeutic redox-responsive nanoplatform.
Fig. 2 Redox-responsive RhB-SiO2@MSN-SS-CPT nanoparticles. (a) TEM images. Core–shell morphology is clearly appreciated in the inset. (b) Diffuse reflectance UV-
vis spectrum showing bands corresponding to CPT (368 nm) and RhB (560 nm).












































Cytotoxicity and intracellular location
Cell uptake experiments were conducted by incubating during
72 h HeLa cancer cells with different concentrations of RhB-
SiO2@MSN-SS-CPT (0.0025 mg mL
21 to 2.5 mg mL21 in CPT
equivalents). Such a long incubation time was stated due to
the observed drug release pattern with GSH and the specific
cytotoxicity mechanism of CPT. The sub-micron size of
nanoparticles and the negative surface charge would probably
favor clathrin mediated internalization of the conjugate inside
HeLa cells via endocytosis pathway, in agreement with recent
research pointed out by different authors for MSN.31–35 The
cytotoxic efficacy of the CPT delivery was studied by MTT
viability assay and compared to the efficacy of molecule 4a and
the pure drug (Fig. 4). The internalized particles were visually
observed by confocal laser scanning microscopy (CLSM). Both
the CPT loaded nanocarrier and free CPT presented very
similar value of half maximal inhibitory concentration (IC50),
which is consistent with previous results comparing the
activity of CPT-loaded nanoparticles with CPT dissolved in
DMSO.31 However, due to its strongly hydrophobic character,
the prodrug molecule showed limited solubility in RPMI
media, even when incorporating it as a DMSO solution. This
hinders the uptake by cells and seriously reduces its efficacy.
Moreover, due to this insolubility, we assume that the
obtained cell viability curve for the 4a compound is a rough
estimation and its cytotoxic activity can’t be accurately
compared. On the other hand, we are aware that some
materials like single wall carbon nanotubes can absorb MTT-
formazan crystallites, leading to overestimation of their real
cytotoxic activity.36 However, it is worth noting that non-
loaded RhB-SiO2@MSN-SH nanoparticles present scarce cyto-
Fig. 3 Cumulative release profile of CPT at 37 uC from RhB-SiO2@MSN-SS-CPT in PBS after addition of GSH (10 mM). (a) Percentage of released drug. (b) Mass of
released drug. In both cases the inset shows the previous non-specific release of CPT in PBS after incubation for 2 h.












































toxicity at the range of concentrations tested (about 80% cell
viability at maximum particle loading in Fig. 4a). Furthermore,
when incubating CPT with corresponding quantities of RhB-
SiO2@MSN-SH nanoparticles, there is no significant change in
the IC50 pattern of the free drug (see Fig. S12 and Table S2 in
the supplementary information3). Consequently, we can say
that in this case mesoporous silica nanoparticles are not
interfering MTT-formazan determination and the obtained
cytotoxicity data are good estimations.
To investigate successful cell entry and intracellular location
of RhB-SiO2@MSN-SS-CPT co-localization experiments were
conducted by incubating HeLa cells with particles. Previously,
it must be taken into account that during incubation in RPMI
supplemented with FBS (10%) nanoparticles are coated by a
protein corona, which can modify the surface charge and then
the process of cellular uptake.35,37 For this reason, Z-potential
was determined after 24 h incubation in cell culture medium.
Results show that Z-potential remains negative after protein
coating, although its value decreases substantially (f = 29.7 ¡
0.8), which should favor nanoparticles entering into cells
through the endocytic pathway.37 In fact, we have found
significant nanoparticle internalization by analyzing confocal
images acquired at different heights along the Z-axis after 24 h
incubation. These show nanoparticles co-localizing with
lysosomes (Fig. 5a–c).
Interestingly, at this incubation time, nanoparticles can also
be seen outside lysosomes (Fig. 5d–f and Fig. S14 in the
supplementary information3), which means that the nanopar-
ticles are able to shift into cytosol. Here, recent research points
to endosomal escape as a bottle-neck for stimuli-responsive
models based on redox-driven intracellular disulfide clea-
vage.38 However, the negative surface charge of RhB-
SiO2@MSN-SS-CPT, even after coating by the protein corona),
can promote the escape of nanoparticles from endo-lysosomal
compartments and enter the cytosol to release their cargo.39
Overall, these observations indicate that nanoparticles were
able to deliver CPT to the cell cytoplasm by entering cells via
endocytosis and later on escaping the endo-lysosomal com-
partment.
CPT intracellular release mechanism
Despite the demonstrated cytoplasmatic location of nanopar-
ticles, the internal release mechanism of most disulfide-based
delivery systems is still to be proven. Although most of the
delivery systems based in disulfide bonds are designed for
intracellular bioreduction, it must also be considered that
bioreduction can also take place in the extracellular space40–42
due to the action of cell-surface oxido-reductases (for example,
protein disulfide isomerase, PDI) and/or chaperones (also
PDI).42 In fact, we found some hydrolysis of the disulfide
linker and CPT release when incubating nanoparticles with
conditioned cell culture medium. To clarify this, we tried to
determine the release efficiency of CPT from nanocarriers in
the cells. For this purpose, we incubated HeLa cells with 20
nM in CPT equivalents of RhB-SiO2@MSN-SS-CPT (corre-
sponding to 0.007 mg mL21 of CPT, the IC50) for 24–72 h.
After incubation, survivor cells were lysed by sonication and,
after centrifugation, CPT was determined in the cytosolic
solutions. The results (Fig. 6) show a significant presence of
released CPT in the cytoplasm that increases from 0 to 48 h,
suggesting the drug is being released after cell internalization.
Then, if we take into account the reasonable stability shown
by RhB-SiO2@MSN-SS-CPT in cell uptake experiments, the
subcellular localization of nanoparticles found in the CLSM
images, and the observed increase of CPT cytosolic levels with
incubation time, we can claim that the mechanism of disulfide
exchange occurs to a large extent within the cell.
Here, while some authors point out the role of GSH for
disulfide cleavage and cytosolic release,8,9,17,21–25,43–46 the
endosomal/lysosomal reducing activity mediated by PDI43 or
endosomal reductase,47 could also bring an early download of
the therapeutic molecule. In addition, it must be taken into
account that carbonate bonds could also be cleaved by
unspecific cytosolic carboxylases.24 To provide further evi-
dence of the suggested GSH-driven mechanism of CPT release
the cytotoxic activity of RhB-SiO2@MSN-SS-CPT was studied by
MTT assay in the presence of a GSH synthesis inhibitor like
BSO.48 BSO was added to a concentration range of 0.1–1 mM
Fig. 4 In vitro MTT cell viability assays in HeLa cell line. (a) RhB-SiO2@MSN-SS-CPT and non-loaded RhB-SiO2@MSN-SH. (b) CPT and compound 4a. All samples were
incubated for 72 h. Top X-axis indicates the concentration of RhB-SiO2@MSH-SH calculated on the base of CPT-loaded nanocarrier.












































24 h before RhB-SiO2@MSN-SS-CPT incorporation to deplete
GSH levels in HeLa cells. Maximum cell resistance to the
antitumor drug due to GSH inhibition is found for 0.1 mM
BSO in the cell culture, (IC50 value triplicates the experiment
with no BSO, Fig. 7 and Table 1). The effect is particularly
strong at low dose range (green zone in Fig. 7a). Further BSO
additions, however, lead to a decrease of IC50, due to the
intrinsic cytotoxicity observed for BSO concentrations above
0.5 mM (see Fig. S15 in supplementary information3). We have
also discarded the possibility that GSH depletion could cause
changes in the activity of the CPT, as a control with CPT and
BSO 0.1 mM showed no significant change over the solely CPT
test (Fig. S16 and Table S3 in supplementary information3).
As an additional control, we have carried out a MTT test with
RhB-SiO2@MSN-SS-CPT and introducing CLQ, an aminoqui-
noline drug that produces severe depletion of GSH levels.49
CLQ (0.15 mM) was added 24 h before CPT-loaded nanopar-
ticles, Results (Fig. S17 and Table S4 in supplementary
information3) show a very powerful inhibition effect on the
nanodrug cytotoxicity, with IC50 becoming four times the
experiment with no inhibitor).
All together, these findings support the role of GSH in the
activation of the intramolecular cyclization that commands
drug release. Nevertheless, we assume that other mechanisms,
mostly referred above, could also be involved in the CPT
intracellular discharge.
Disulfide vs. ester linkage for CPT intracellular delivery
We have recently published the first silica-based nanocarrier
for delivery of covalently coupled CPT.14 An ester bond,
sensitive to cytoplasmatic carboxylases provided a slow release
mechanism of the drug but with lower efficiency than the
naked drug, due to sterical restrictions that affect the
enzymatic hydrolysis of the ester linker and prevent a
complete releasing process.50,51 Conversely, since thiol spe-
cies, including GSH are more abundant in tumor cells than in
normal cells, MSN-containing disulfide-based delivery systems
are expected to release completely the delivered therapeutic
payload upon exposure to thiols.45,52–55 Consistently with this
principle, a CPT-silica ester conjugate (RhB-SiO2@MSN-COO-
Fig. 5 Co-localization studies of RhB-SiO2@MSN-SS-CPT in HeLa cells. Confocal images of the same Z plane were obtained for (a) Lysotracker and for (b) Rhodamine
B-labeled nanoparticles, and (c) merged afterwards to demonstrate that some of the nanoparticles are allocated inside acidic organelles labeled by Lysotracker. (d)
Inset in c. (e) Same image as in d with higher background-threshold for green signal. White row indicates the line depicted for (f) signal intensity plot. Numbers
correspond to nanoparticles in the cytosol (1), nanoparticles colocalizing with lysosomes (2) and lysosomes without nanoparticles (3).
Fig. 6 Cumulative release profile of CPT from RhB-SiO2@MSN-SS-CPT in
cytosolic solutions obtained after incubating HeLa cells with RhB-SiO2@MSN-SS-
CPT (20 nm in CPT equivalents) for 24–72 h, and further cell lysis by sonication.












































CPT) with equivalent drug content showed a significant higher
IC50 value than RhB-SiO2@MSN-SS-CPT (Table 1, Fig. 8).
The suggested cell uptake process and drug release
mechanism of RhB-SiO2@MSN-SS-CPT is summarized in
Scheme 2. Based on this delivery profile, we hypothesize that
by modifying the length of the C-chain in the disulfide linker
(e.g., by incorporation of compounds 4b or 4c) this novel
therapeutic system can introduce additional control over
intracellular drug release.
Conclusion
We have developed a novel nanoparticulated core-shell system
combining therapeutic activity and imaging at the subcellular
level, based in an external covalent coupling model with a
Fig. 7 Inhibition of intracellular CPT release with BSO in HeLa cell line as stated by in vitro MTT cell viability assay. (a) Effect of BSO 0.1 mM in cytotoxic activity of RhB-
SiO2@MSN-SS-CPT. The green zone corresponds to the range of CPT concentrations where the strongest inhibition episode happens. (b) Evolution of IC50 value for
RhB-SiO2@MSN-SS-CPT with the concentration of BSO.
Table 1 IC50 values for tested samples in HeLa cells
Entry IC50
a
CPT 0.0064 ¡ 0.0007
4a 0.1862 ¡ 0.0225
RhB-SiO2@MSN-SS-CPT 0.0067 ¡ 0.0005
RhB-SiO2@MSN-SS-CPT + BSO 0.1 mM 0.0211 ¡ 0.0013
RhB-SiO2@MSN-COO-CPT 0.0842 ¡ 0.0164
a CPT concentration (mg mL21). Data indicate the mean ¡ SEM (mg
mL21) of 3 experiments.
Fig. 8 In vitro MTT cell viability assay of the CPT-silica ester conjugate RhB-
SiO2@MSN-COO-CPT and non-loaded RhB-SiO2@MSN-COOH. Top X-axis
indicates the concentration of RhB-SiO2@MSH-COOH calculated on the base of
CPT-loaded nanocarrier.
Scheme 2 Artistic representation of cell uptake process and drug release
mechanism of RhB-SiO2@MSN-SS-CPT in HeLa cells. (a) Cell internalization by
endocytic pathway of the multifunctional nanoparticles and co-localization in
endo-lysosomes. (b) Escape of nanoparticles from endo-lysosomal compart-
ments to the cytosol and activation of the redox-responsive linking system by
GSH-driven disulfide reduction and further intermolecular cyclization, resulting
in the release of free CPT and the corresponding thiolactone. (c) Entrance of CPT
into the cell nucleus and inhibition of topoisomerase I during DNA replication.












































cleavable disulfide linker able to release the naked drug by
means of an intramolecular cyclization mechanism and an
internal fluorophore. For this purpose, a new synthetic
strategy has been implemented by direct incorporation of
CPT prodrugs on the nanocarrier. The negative surface charge
of this system allows nanoparticles to escape from endo-
lysosomes and enter the cytosol where the disulfide bridge can
be reduced by a GSH-driven mechanism that provides
controlled release of the drug with identical cytotoxic activity
to the naked drug. The valuable stability provided in
physiological medium points to an optimized delivery system
able to surpass extracellular and intracellular barriers in order
to monitor a fine control over releasable species.
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